Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

Pancreas Clinical Trial

Official title: Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

Status Recruiting

Clinical Trial Summary

This is a randomized study that will enroll patients scheduled for an endoscopic ultrasound biopsy of a pancreas lesion to be in the heparin or saline group during the procedure. The purpose of this study is to examine the effect of blood contamination, heparin priming of the fine needle biopsies, and pass number on tumor tissue quality in fine needle biopsies. The hypothesis for this study is that fine needle biopsy tissue quality of pancreatic masses decreases with increasing pass number due to blood contamination; this blood contamination can be ameliorated with priming of the needle with an anticoagulant such as heparin.

Clinical Trial Description

This study was amended at the Institutional Review Board (IRB) after having enrolled only two participants. Following the amendment, the responsible party changed and with that change some adjustments were made to the interventions, analysis and some outcomes. ;

Related Conditions & MeSH terms

• Mass Lesion
• Pancreas

• NCT number: NCT04764396
• Study type: Interventional
• Source: University of Michigan
• Contact: Eileen Carpenter, MD
• Phone: 734-936-4385
• Email: eicarpen@umich.edu
• Status: Recruiting
• Phase: N/A
• Start date: March 12, 2021
• Completion date: August 2025